Vivani Medical (VANI) Price & Analysis

Compare

761 Followers

VANI Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.91 - $1.80

Previous CloseN/A

Volume36.09K

Average Volume (3M)115.75K

Market Cap

$78.79M

Enterprise Value$67.81M

Total Cash (Recent Filing)$13.01M

Total Debt (Recent Filing)$18.94M

Price to Earnings (P/E)―

Beta1.01

Next Earnings

Aug 19, 2025

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding59,243,904

10 Day Avg. Volume86,116

30 Day Avg. Volume115,754

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.86

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-2.76

Forecast

1Y Price Target

$4.00

Price Target Upside200.75% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsAll subjects implanted with NPM-115 in the Phase 1 LIBERATE-1 study experienced successful implantation with no unexpected adverse events, indicating a well-tolerated procedure.

Financial PositionThe company closed two equity financings, resulting in a pro forma cash position of approximately $24.8M, providing a cash runway to mid-2026.

Market PotentialThe GLP-1 and obesity treatment market is expanding and can accommodate multiple players, offering opportunities for Vivani's platform.

Bears Say

Regulatory RisksRisks include the potential failure of NPM-115 in clinical trials, failure to secure regulatory approval, failure to achieve commercial success, and dilution risk.

Stock DilutionMore dilution may be required for future financing considering the current share price trading near a 52-week low and overall market dynamics.

Vivani Medical News

Vivani Medical Holds 2025 Annual Stockholders Meeting

Vivani Medical ( ($VANI) ) has issued an announcement. The 2025 Annual Meeting of Stockholders of Vivani Medical,...

1M ago

VANI

Vivani Medical Updates on Exenatide Implant Progress

Vivani Medical ( ($VANI) ) has issued an announcement. Vivani Medical has released a corporate slide presentation to...

2M ago

VANI

Vivani Medical Appoints New CFO Amid Leadership Change

Vivani Medical ( ($VANI) ) just unveiled an update. On June 10, 2025, Brigid Makes announced her resignation...

2M ago

VANI

Vivani Medical appoints Baldor as Chief Financial Officer

Vivani Medical (VANI) announced the appointment of Anthony Baldor as Chief Financial Officer. Baldor succeeds Brigid Makes, who...

2M ago

VANI

Vivani Medical Announces Spin-Off of Cortigent Subsidiary

Vivani Medical ( ($VANI) ) has issued an update. On May 29, 2025, Vivani Medical announced the planned...

2M ago

VANI

Vivani Medical files Form 10 registration statement for Cortigent spin-off

Vivani Medical (VANI) announced that Cortigent, a wholly owned subsidiary of the Company that develops brain implant devices...

2M ago

VANI

Vivani Medical Reports Q1 2025 Results and Strategic Updates

Vivani Medical, Inc. ( ($VANI) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

VANI

Vivani Medical: Promising Developments and Financial Stability Support Buy Rating

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Vivani Medical (VANI – Research Report) today and...

3M ago

VANI

Vivani Medical’s Strong Financial Position and Promising Clinical Progress Earns Buy Rating

Vivani Medical (VANI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday....

3M ago

VANI

Vivani Medical Secures $3 Million in Share Purchase

Vivani Medical ( ($VANI) ) has shared an announcement. On May 12, 2025, Vivani Medical entered into a...

3M ago

VANI

Vivani Medical’s Strategic Expansion and Promising Developments Drive Buy Rating

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Vivani Medical (VANI – Research Report) and...

4M ago

VANI

Vivani Medical, Okava expand collaboration to develop OKV-119 for dogs

Vivani Medical (VANI) and Okava Pharmaceuticals announced an expansion of their collaboration to include dogs in the development...

4M ago

VANI

Vivani Medical’s Promising Obesity Treatment Developments and Strong Financial Position Justify Buy Rating

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Vivani Medical (VANI...

4M ago

VANI

Morning Movers: Mr. Cooper surges after Rocket Companies takeover deal

Stock index futures are falling sharply on Monday as investor concerns mount about President Donald Trump’s upcoming announcement...

4M ago

FBK

HUT

VANI FAQ

What was Vivani Medical’s price range in the past 12 months?

Vivani Medical lowest stock price was $0.91 and its highest was $1.80 in the past 12 months.

What is Vivani Medical’s market cap?

Vivani Medical’s market cap is $78.79M.

When is Vivani Medical’s upcoming earnings report date?

Vivani Medical’s upcoming earnings report date is Aug 19, 2025 which is in 14 days.

How were Vivani Medical’s earnings last quarter?

Vivani Medical released its earnings results on May 13, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.11.

Is Vivani Medical overvalued?

According to Wall Street analysts Vivani Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vivani Medical pay dividends?

Vivani Medical does not currently pay dividends.

What is Vivani Medical’s EPS estimate?

Vivani Medical’s EPS estimate is -0.1.

How many shares outstanding does Vivani Medical have?

Vivani Medical has 59,243,904 shares outstanding.

What happened to Vivani Medical’s price movement after its last earnings report?

Vivani Medical reported an EPS of -$0.11 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.81%.

Which hedge fund is a major shareholder of Vivani Medical?

Currently, no hedge funds are holding shares in VANI

Vivani Medical Stock Smart Score

Neutral

Fundamentals

Return on Equity

-117.76%

Trailing 12-Months

Asset Growth

-34.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vivani Medical

Vivani Medical (VANI) is a medical technology company specializing in the development of innovative implantable solutions for chronic disease management. The company operates in the healthcare sector, focusing on creating products that enhance patient outcomes and quality of life. Vivani Medical's core products include advanced drug delivery systems and neurostimulation devices that are designed to address various medical conditions.

Vivani Medical (VANI) Earnings & Revenues

VANI Earnings Data >

VANI Stock 12 Month Forecast

Average Price Target

$4.00

▲(200.75%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","5":"$5","1.25":"$1.25","2.5":"$2.5","3.75":"$3.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.25,2.5,3.75,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Dec<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.04,1.2676923076923077,1.4953846153846153,1.7230769230769232,1.9507692307692308,2.1784615384615384,2.4061538461538463,2.6338461538461537,2.8615384615384616,3.0892307692307694,3.316923076923077,3.5446153846153847,3.7723076923076926,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.04,1.2676923076923077,1.4953846153846153,1.7230769230769232,1.9507692307692308,2.1784615384615384,2.4061538461538463,2.6338461538461537,2.8615384615384616,3.0892307692307694,3.316923076923077,3.5446153846153847,3.7723076923076926,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.04,1.2676923076923077,1.4953846153846153,1.7230769230769232,1.9507692307692308,2.1784615384615384,2.4061538461538463,2.6338461538461537,2.8615384615384616,3.0892307692307694,3.316923076923077,3.5446153846153847,3.7723076923076926,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.25,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.09,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >